PMID- 24758564
OWN - NLM
STAT- MEDLINE
DCOM- 20150204
LR  - 20211021
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 12
DP  - 2014 Apr 24
TI  - Clinicopathological significance of cancer stem cells marked by CD133 and 
      KAI1/CD82 expression in laryngeal squamous cell carcinoma.
PG  - 118
LID - 10.1186/1477-7819-12-118 [doi]
AB  - BACKGROUND: Presently, CD133 is one of the hottest markers to characterize cancer 
      stem cells and KAI1/CD82 is reported as an important marker for the metastasis 
      and prognosis of many cancers. The purpose of our study is to explore the 
      relationship between cancer stem cells (CSCs) marked by CD133 and KAI1/CD82 
      expression and the clinicopathological characteristics of patients with laryngeal 
      squamous cell carcinoma (LSCC). METHODS: Immunohistochemical analysis was used to 
      detect the expression of CD133 and KAI1/CD82 in 83 archival surgical specimens of 
      human LSCC and 83 cases of normal laryngeal tissues. RESULTS: In LSCC, positive 
      rates of 49.4% and 41.0% were obtained for CD133 and KAI1/CD82, respectively. The 
      expression of CD133 in LSCC tissues was significantly higher than that in normal 
      tissues (P<0.001), and the expression of CD133 was positively associated with 
      pTNM stage (P=0.005), pathological grade (P=0.001), and lymph node metastasis 
      (P<0.001). The reduced expression of KAI1/CD82 was present in LSCC tissues. The 
      positive rate of KAI1/CD82 expression was negatively correlated with pTNM stage 
      (P=0.014), pathological grade (P<0.001), and lymph node metastasis (P=0.007). A 
      correlation analysis showed that there was a negative relationship between the 
      expression of CD133 and KAI1/CD82 protein in LSCC tissues (P<0.001). By 
      Kaplan-Meier analysis, the expression of CD133 was negatively correlated with 
      overall survival (OS) (log-rank=40.949, P<0.001) and disease-free survival (DFS) 
      (log-rank=39.307, P<0.001) time of LSCC. The expression of KAI1/CD82 was 
      positively correlated with OS (log-rank=40.279, P<0.001) and DFS 
      (log-rank=39.271, P<0.001) time of LSCC. Cox regression analysis: the expression 
      of CD133 and KAI1/CD82, and pTNM stages were independent prognostic factors of 
      LSCC (P<0.05). CONCLUSIONS: Thus the detection of CD133 and KAI1/CD82 proteins 
      may be used as a potential indicator of LSCC prognosis.
FAU - Yu, Lan
AU  - Yu L
FAU - Zhou, Lei
AU  - Zhou L
FAU - Wu, Shiwu
AU  - Wu S
AD  - Department of Pathology, the First Hospital Affiliated to Bengbu Medical College, 
      Bengbu Medical College, 800 Zhihuai Ave, Longzihu, Bengbu, Anhui, China. 
      honghongwuwu@sohu.com.
FAU - Gong, Xiaomeng
AU  - Gong X
FAU - Feng, Zhenzhong
AU  - Feng Z
FAU - Ma, Li
AU  - Ma L
FAU - Zhu, Bo
AU  - Zhu B
FAU - Yao, Nan
AU  - Yao N
FAU - Wang, Danna
AU  - Wang D
FAU - Dong, Huiming
AU  - Dong H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140424
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (AC133 Antigen)
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD82 protein, human)
RN  - 0 (Glycoproteins)
RN  - 0 (Kangai-1 Protein)
RN  - 0 (PROM1 protein, human)
RN  - 0 (Peptides)
SB  - IM
MH  - AC133 Antigen
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD/*metabolism
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Squamous Cell/metabolism/mortality/*secondary
MH  - Female
MH  - Follow-Up Studies
MH  - Glycoproteins/*metabolism
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Kangai-1 Protein/*metabolism
MH  - Laryngeal Neoplasms/metabolism/mortality/*pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplastic Stem Cells/metabolism/*pathology
MH  - Peptides/*metabolism
MH  - Prognosis
MH  - Survival Rate
PMC - PMC4012248
EDAT- 2014/04/25 06:00
MHDA- 2015/02/05 06:00
PMCR- 2014/04/24
CRDT- 2014/04/25 06:00
PHST- 2013/04/28 00:00 [received]
PHST- 2014/04/07 00:00 [accepted]
PHST- 2014/04/25 06:00 [entrez]
PHST- 2014/04/25 06:00 [pubmed]
PHST- 2015/02/05 06:00 [medline]
PHST- 2014/04/24 00:00 [pmc-release]
AID - 1477-7819-12-118 [pii]
AID - 10.1186/1477-7819-12-118 [doi]
PST - epublish
SO  - World J Surg Oncol. 2014 Apr 24;12:118. doi: 10.1186/1477-7819-12-118.